390P Vepdegestrant, a proteolysis targeting chimera (PROTAC) estrogen receptor (ER) degrader, in ER+/human epidermal growth factor receptor 2 (HER2)- advanced breast cancer: Update of dose escalation results from a phase I/II trial
Hamilton, E.P., Han, H., Schott, A., Tan, A., Nanda, R., Juric, D., Hunter, N., Munster, P., Fang, B., Zahrah, G., Ranciato, J., Gedrich, R., Zhi, E., Zhang, Y., Tan, W., Mather, C., Perkins, J., Anderson, S., Hurvitz, S.A.
Published in Annals of oncology (01.10.2023)
Published in Annals of oncology (01.10.2023)
Get full text
Journal Article
256TiP TACTIVE-E: Phase Ib study of ARV-471, a PROteolysis TArgeting Chimera (PROTAC) estrogen receptor (ER) degrader, in combination with everolimus in ER+/human epidermal growth factor receptor 2 (HER2)- advanced breast cancer
Philipovskiy, A., Schott, A., Cortés, J., Ivie, S., Gedrich, R., Zhi, E., Ranciato, J., Perkins, J., Hamilton, E.
Published in ESMO open (01.05.2023)
Published in ESMO open (01.05.2023)
Get full text
Journal Article
Litter dynamics along stream, riparian and upslope areas following hurricane Hugo, Luquillo Experimental Forest, Puerto Rico
Vogt K.A, Vogt D.J, Boon P, Covich A, Scatena F.N, Asbjornsen H, O'Hara J.L, Perez J, Siccama T.G, Bloomfield J
Published in Biotropica (01.12.1996)
Published in Biotropica (01.12.1996)
Get more information
Journal Article
154TiP TACTIVE-N: Open-label, randomized, noncomparative neoadjuvant phase 2 study of ARV-471, a PROteolysis TArgeting Chimera (PROTAC) estrogen receptor (ER) degrader, or anastrozole in postmenopausal women with ER+/human epidermal growth factor receptor 2 (HER2)- localized breast cancer
Fasching, P.A., Clifton, K., Katashvili, Z., Nemsadze, G., Makharadze, T., Arkania, E., Gogishvili, M., Lachowicz, M., Gedrich, R., Ranciato, J., Zhi, E., Perkins, J., Jañez, N. Martinez, Hurvitz, S.A.
Published in ESMO open (01.05.2023)
Published in ESMO open (01.05.2023)
Get full text
Journal Article